Catalyst Biosciences Inc.
Catalyst Biosciences Inc. is a San Francisco company formed around proprietary technology exclusively licensed from the University of California, San Francisco, to develop engineered proteases as a new class of protein therapeutics.
Proteases are naturally occurring protein-degrading enzymes that are catalytic in nature. Each protease molecule is capable of inactivating hundreds to thousands of target molecules, resulting in better target saturation and lowered dosing. Catalyst intends to harness the power of these enzymes as biopharmaceuticals by engineering them towards site-specific cleavage of disease-causing proteins.
RCT is investing in Catalyst through RCT BioVentures. Co-investors include Burrill and Co., Soffinova Venture Partners and Novartis Bioventures.
Inventors/Founders
Charles S. Craik, Ph.D., University of California, San Francisco; Sandra Waugh Ruggles, Ph.D., Catalyst Biosciences; Christopher D. Thanos, Ph.D., Catalyst Biosciences; Jack T. Nguyen, Ph.D.
Catalyst Contact
Nassim Usman, Ph.D., CEO, (650) 266-8674
RCT Contact
Shaun A. Kirkpatrick, President & CEO